Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Vernalis Collaborates with Unison to Discover Drugs for “Undruggable” Bacterial Target

publication date: Sep 6, 2022

Vernalis Research formed a research collaboration with Unison Medicines to design small molecules for an undisclosed, hard-to-target bacterial site. Vernalis is a Cambridge UK structure-based drug discovery company that was acquired by Chengdu HitGen in 2020.  Unison, a Cambridge, MA startup, develops novel drugs for drug resistant infections. Vernalis will use its drug discovery technology to find small molecules for the Unison target, which has previously been considered undruggable. Unison will finance Vernalis’ work and be responsible for paying milestones and royalties on any revenues. Vernalis contributed to Unison's first financing round. More details....

Stock Symbol: (SHA: 688222)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here